Optimi Health Completes Psilocybin Production for Health Canada-Approved Phase 2 MDD Trial and Commercial TRD Supply

VANCOUVER, British Columbia, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) ("Optimi" or the "Company"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced the completion and quality release of a production batch of 5mg naturally derived psilocybin capsules, manufactured end to end at the Company’s cGMP facility in Princeton, British Columbia, under a Health Canada Drug Establishment Licence. The batch will supply the recently announced Phase 2 clinical trial of psilocybin-assisted therapy evaluating psilocybin-assisted therapy in the treatment of major depressive disorder (“MDD”) and commercial customers in Australia.

This Health Canada-authorized trial is a multisite, open-label study of up to 200 participants, each receiving a single supervised dose of Optimi’s . Patient dosing is expected to be completed by the end of 2027. Data from the trial are intended to assess the safety and efficacy of psychedelic-assisted therapy in the hope of building the necessary evidentiary base to support registration in Canada and other jurisdictions.